775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study

Risankizumab (RZB) is a monoclonal antibody against interleukin-23, a key cytokine in the pathogenesis of inflammatory bowel disease. Phase 2 studies have shown efficacy and safety of RZB in patients with Crohn’s disease (CD). Here we report results of ADVANCE (NCT03105128), a double-blind randomized phase 3 study evaluating efficacy and safety of RZB as induction therapy in patients with moderate to severe CD.